Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 19/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4740700 | 0.90 | ADRB2 (0.45) | ADRB2ADRB1DRD3 | |
| SCHEMBL4753883 | 0.89 | ADRB2 (0.50) | ADRB2ADRB1DRD3DRD2ADRA1D | |
| SCHEMBL4739373 | 0.84 | ADRB2 (0.42) | ADRB2ADRB1DRD3DRD2ADRA1D | |
| SCHEMBL4802178 | 0.81 | ADRB2 (0.38) | ADRB2ADRB1DRD3DRD2ADRA1D | |
| SCHEMBL4742320 | 0.79 | ADRB2 (0.45) | ADRB2 | |
| SCHEMBL4738383 | 0.79 | ADRB2 (0.45) | ADRB2 | |
| SCHEMBL4742671 | 0.79 | ADRB2 (0.38) | ADRB2ADRB1DRD3 | |
| SCHEMBL4741385 | 0.79 | ADRB2 (0.44) | ADRB2 | |
| SCHEMBL4784314 | 0.78 | ADRB2 (0.43) | ADRB2 | |
| SCHEMBL4741160 | 0.77 | ADRB2 (0.44) | ADRB2ADRB1DRD2ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008149110-A1 | BICYCLOR [2.2.1] HEPT-7-YLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES AND CONDITIONS IN WHICH M3 MUSCARINIC RECEPTOR ACTIVITY AND BETA-ADRENERGIC ACTIVITY ARE IMPLICATED | ARGENTA DISCOVERY LIMITED (GB) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008149110-A1 | BICYCLOR [2.2.1] HEPT-7-YLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES AND CONDITIONS IN WHICH M3 MUSCARINIC RECEPTOR ACTIVITY AND BETA-ADRENERGIC ACTIVITY ARE IMPLICATED | ARGENTA DISCOVERY LIMITED (GB) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008096129-A1 | NITROGEN CONTAINING HETROCYCLIC COMPOUNDS USEFUL AS BIFUNCTIONAL MODULATORS OF M3 RECEPTORS AND BETA- 2 RECEPTORS | ARGENTA DISCOVERY LTD (GB) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008096129-A1 | NITROGEN CONTAINING HETROCYCLIC COMPOUNDS USEFUL AS BIFUNCTIONAL MODULATORS OF M3 RECEPTORS AND BETA- 2 RECEPTORS | ARGENTA DISCOVERY LTD (GB) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008096127-A2 | BICYCLO[2.2.1]HEPT-7-YLAMINE DERIVATIVES AND THEIR USE AS M3 MUSCARINIC RECEPTOR MODULATORS | ARGENTA DISCOVERY LTD (GB) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008096127-A2 | BICYCLO[2.2.1]HEPT-7-YLAMINE DERIVATIVES AND THEIR USE AS M3 MUSCARINIC RECEPTOR MODULATORS | ARGENTA DISCOVERY LTD (GB) | 2008-08-14 | — | — | WO | disclosed |